(2S)-2-[[3-chloro-6-(furan-2-ylmethylcarbamoyl)-1-hydroxynaphthalene-2-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[3-chloro-6-(furan-2-ylmethylcarbamoyl)-1-hydroxynaphthalene-2-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
• 化学式: C₂₇H₂₃ClN₂O₈S
• 分子量: 571.0
• InChiKey: WGXLBWSRKXVWRP-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  171
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT
  申请人：SARCODE BIOSCIENCE INC.

  公开号：US20140141062A1

  公开（公告）日：2014-05-22

  The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
• US9045457B2
  申请人：——

  公开号：US9045457B2

  公开（公告）日：2015-06-02